To recover your password please fill in your email address
Please fill in below form to create an account with us
Single arm, open label, signal seeking, phase II trial of the activity of tucatinib plus trastuzumab in patients with tumours harbouring HER2 amplifications or mutations
|
Trial Summary: |
The aim of this MoST substudy is to assess the clinical activity of tucatinib in combination with trastuzumab in a population of patients with advanced tumours harbouring HER2 amplification or mutations. |
|
Supported By: |
|
|
Eligibility: |
Adult patients with tumours expressing HER2, if a somatic HER2 amplification or mutation is identified in their tumour, their primary cancer is not breast or gastric cancer (for the HER2 amplified group) and they have not received any previous HER2 directed therapy. |
|
Registration ID: |
ACTRN12620000767909 |
|
Participation: |
National |
|
Status: |
In follow-up |
|
Activation Date: |
18/02/2022 |
|
Chairs: |
Prof David Goldstein |
|
Contact: |